Keywords: b-ms, ipilimumab, doubles, one-year, survival, advanced, melanoma

B-MS' ipilimumab doubles one-year survival of advanced melanoma patients

Article | 22 September 2008

Print This

US drug major Bristol-Myers Squibb presented data from three mid-stage trials in advanced melanoma showing that half of patients on ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in